Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial - PubMed (original) (raw)
Clinical Trial
. 2012 Sep 19;4(152):152ra127.
doi: 10.1126/scitranslmed.3004214.
David Hessl, Barbara Rathmell, Peter Zarevics, Maryann Cherubini, Karen Walton-Bowen, Yi Mu, Danh V Nguyen, Joseph Gonzalez-Heydrich, Paul P Wang, Randall L Carpenter, Mark F Bear, Randi J Hagerman
Affiliations
- PMID: 22993294
- DOI: 10.1126/scitranslmed.3004214
Clinical Trial
Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial
Elizabeth M Berry-Kravis et al. Sci Transl Med. 2012.
Abstract
Research on animal models of fragile X syndrome suggests that STX209, a γ-aminobutyric acid type B (GABA(B)) agonist, might improve neurobehavioral function in affected patients. We evaluated whether STX209 improves behavioral symptoms of fragile X syndrome in a randomized, double-blind, placebo-controlled crossover study in 63 subjects (55 male), ages 6 to 39 years, with a full mutation in the FMR1 gene (>200 CGG triplet repeats). We found no difference from placebo on the primary endpoint, the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. In the other analyses specified in the protocol, improvement was seen on the visual analog scale ratings of parent-nominated problem behaviors, with positive trends on multiple global measures. Post hoc analysis with the ABC-Social Avoidance scale, a newly validated scale for the assessment of fragile X syndrome, showed a significant beneficial treatment effect in the full study population. A post hoc subgroup of 27 subjects with more severe social impairment showed improvements on the Vineland II-Socialization raw score, on the ABC-Social Avoidance scale, and on all global measures. STX209 was well tolerated, with 8% incidences of sedation and of headache as the most frequent side effects. In this exploratory study, STX209 did not show a benefit on irritability in fragile X syndrome. Nonetheless, our results suggest that GABA(B) agonists have potential to improve social function and behavior in patients with fragile X syndrome.
Similar articles
- STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.
Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH. Erickson CA, et al. J Autism Dev Disord. 2014 Apr;44(4):958-64. doi: 10.1007/s10803-013-1963-z. J Autism Dev Disord. 2014. PMID: 24272415 Clinical Trial. - Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.
Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, Brynczka C, Rush R, Thomas A, Paylor R, Warren ST, Vanderklish PW, Kind PC, Carpenter RL, Bear MF, Healy AM. Henderson C, et al. Sci Transl Med. 2012 Sep 19;4(152):152ra128. doi: 10.1126/scitranslmed.3004218. Sci Transl Med. 2012. PMID: 22993295 Free PMC article. - Arbaclofen in fragile X syndrome: results of phase 3 trials.
Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M, Zarevics P, Walton-Bowen K, Wang P, Bear MF, Carpenter RL. Berry-Kravis E, et al. J Neurodev Disord. 2017 Jun 12;9:3. doi: 10.1186/s11689-016-9181-6. eCollection 2017. J Neurodev Disord. 2017. PMID: 28616094 Free PMC article. - Clinical potential, safety, and tolerability of arbaclofen in the treatment of autism spectrum disorder.
Frye RE. Frye RE. Drug Healthc Patient Saf. 2014 May 10;6:69-76. doi: 10.2147/DHPS.S39595. eCollection 2014. Drug Healthc Patient Saf. 2014. PMID: 24872724 Free PMC article. Review. - ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen).
Hopkins CR. Hopkins CR. ACS Chem Neurosci. 2011 Aug 17;2(8):381. doi: 10.1021/cn200061g. Epub 2011 Jul 6. ACS Chem Neurosci. 2011. PMID: 22860166 Free PMC article. Review.
Cited by
- Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.
Bagni C, Tassone F, Neri G, Hagerman R. Bagni C, et al. J Clin Invest. 2012 Dec;122(12):4314-22. doi: 10.1172/JCI63141. Epub 2012 Dec 3. J Clin Invest. 2012. PMID: 23202739 Free PMC article. - Opportunities and challenges in modeling human brain disorders in transgenic primates.
Jennings CG, Landman R, Zhou Y, Sharma J, Hyman J, Movshon JA, Qiu Z, Roberts AC, Roe AW, Wang X, Zhou H, Wang L, Zhang F, Desimone R, Feng G. Jennings CG, et al. Nat Neurosci. 2016 Aug 26;19(9):1123-30. doi: 10.1038/nn.4362. Nat Neurosci. 2016. PMID: 27571191 - A MEG Study of Acute Arbaclofen (STX-209) Administration.
Roberts TPL, Bloy L, Blaskey L, Kuschner E, Gaetz L, Anwar A, Ku M, Dipiero M, Bennett A, Edgar JC. Roberts TPL, et al. Front Integr Neurosci. 2019 Dec 4;13:69. doi: 10.3389/fnint.2019.00069. eCollection 2019. Front Integr Neurosci. 2019. PMID: 31866839 Free PMC article. - Disentangling the heterogeneity of autism spectrum disorder through genetic findings.
Jeste SS, Geschwind DH. Jeste SS, et al. Nat Rev Neurol. 2014 Feb;10(2):74-81. doi: 10.1038/nrneurol.2013.278. Epub 2014 Jan 28. Nat Rev Neurol. 2014. PMID: 24468882 Free PMC article. Review. - The challenges of clinical trials in fragile X syndrome.
Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G, Ufer M, Des Portes V, Gomez-Mancilla B. Jacquemont S, et al. Psychopharmacology (Berl). 2014 Mar;231(6):1237-50. doi: 10.1007/s00213-013-3289-0. Epub 2013 Oct 31. Psychopharmacology (Berl). 2014. PMID: 24173622 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical